Purpose To identify baseline characteristics and long-term prognostic factors in non-transplant patients with unre-
Introduction
Yttrium-90 radioembolization (Y90) is a minimally invasive outpatient procedure offered for unresectable hepatocellular carcinoma (HCC). While once reserved only for the salvage setting in patients with multifocal disease and/ or portal vein tumor thrombus, radioembolization is now applied across the spectrum of early to advanced HCC Barcelona Clinic Liver Cancer Stages (BCLC) [1] [2] [3] [4] . Most patients with HCC are never eligible for curative surgery like hepatic resection or transplantation owing to the extent of disease at presentation, presence of portal hypertension, and the limited availability of transplant organs. In BCLC Stage A patients, chemoembolization and radioembolization have demonstrated similar median survivals of 54.2 and 53.4 months, respectively [5, 6] . In this retrospective study, we aimed to identify factors associated with prolonged survival after Y90 in the absence of surgical resection or transplantation. Among 1000 patients treated with Y90, a subgroup of non-surgical HCC patients who had atypically long survival of three or more years after intra-arterial therapy with Y90 were defined as ''Super Survivors'' [4] . Our hypothesis based on the existing Y90 evidence in BCLC Stage A patients was that Super Survivors would be young, with excellent Eastern Cooperative Oncology Group (ECOG) performance status (0-1), and have primarily preserved liver function at baseline (ChildPugh Class A), solitary, noninvasive disease, and the majority would often go on to eventually receive ablation per the American Association for the Study of Liver Diseases (AASLD) guidelines for BCLC Stage A disease [7] .
Methods
The study was a retrospective observational cohort study under our open-label protocol. We queried the Interventional Oncology Registry for all patients who underwent radioembolization (NCT00532740) and complied with the Health Insurance Portability and Accountability Act. Of 1000 HCC patients treated with Y90 between December 1, 2003, and March 31, 2017, 67 patients met the inclusion criteria as Super Survivors. Each patient was reviewed and discussed by a multidisciplinary tumor board including hepatology, oncology, interventional radiology, and transplant surgery.
Study Eligibility
Inclusion criteria included (1) image-or biopsy-proven HCC according to AASLD guidelines [7] ; (2) treatment with Y90, as allocated by a multidisciplinary team; and (3) survival of 3 or more years. Exclusion criterion was (1) surgery including resection or transplantation at any time during 3-year follow-up.
Evaluation and Staging
Patient demographics, risk factors, etiology of liver disease, ECOG performance status, BCLC staging, albuminbilirubin (ALBI) score, and Child-Pugh class were recorded.
Y90 Treatments
Visceral angiography and technetium-99m scintigraphy were used to estimate lung shunting, identify extrahepatic perfusion, and perform coil embolization if necessary. Included data and the definition for technical success follow previously published reporting standards for radioembolization [8] . Glass microspheres (TheraSphere Ò , BTG International) were used in each case with treatment on an outpatient basis. Infusions were completed at the segmental or lobar level with adjustments as previously described for radiation segmentectomy and extended-shelflife (ESL) protocols [9] [10] [11] [12] .
Outcome Variables
• Security Death Index with analyses calculated from the day of first radioembolization to death (in months) by the KM method.
• Interval treatment The median time to subsequent treatment, the number of treatments, and the conversion to other liver-directed therapies (denoted by ''Y90-[ X'' for Y90 followed by X) were recorded for each patient. The maximum and minimum treatment-free interval was also calculated for each patient and defined as the longest and shortest period between any two treatments, respectively.
Statistics
Medians are reported with 95% confidence intervals (CIs) and mean ± standard deviation. Overall survival and TTP outcomes were estimated using the KM method, and subgroups were compared with the log-rank test. The hazard ratio and 95% CI were estimated using Cox proportional hazards regression. All analyses were performed using STATA v14.0 (StataCorp, College Station, TX, USA); p \ 0.05 was considered significant.
Results

Baseline Characteristics
The baseline characteristics for the cohort are shown in Table 1 . Solitary lesions were present in 59.7% of patients. Previous liver-directed therapy was received in 13.4% (n = 9) of patients. Thirteen patients (19.4%) were referred for treatment from outside hospitals.
Treatment and Dosimetry
All 67 patients were treated successfully. Segmental Y90 was performed in 45/67 (67.2%) patients; 22 (32.8%) were lobar treatments. The average number of Y90 treatments was 2.52 ± 1.69 over the course of follow-up. The mean dose was 116 Gy for lobar and 206 Gy for segmental radioembolization (Supplemental Table 1 
Laboratory Toxicities
Supplemental Table 2 (online only) summarizes laboratory toxicities. Grade 3 ? toxicities were elevated AST 2/67 (3.0%), hypoalbuminemia 1/67 (1.5%), and elevated bilirubin 4/67 (6.0%).
Imaging Outcomes
Supplemental Time to Progression Figure 1 shows TTP. The rate of progression was 36/67 patients (53.7%) over the course of follow-up, and the median TTP was 33.7 months (95% CI 22.0-36.9). 
Interval Treatment
During follow-up, 56.7% (n = 38) of Super Survivors were treated with Y90 and no other modality (isolated Y90), 19 .4% (n = 13) later underwent RFA, 14.9% (n = 10) later received systemic therapy with sorafenib, 4.5% (n = 3) later received TACE, 3% (n = 2) later received bland embolization, and one patient received sorafenib in combination with Y90. The average number of Y90 treatments was 2.11 ± 1.37 for isolated Y90 (no alternate therapy), 3.69 ± 2.14 for Y90 followed by RFA, 2.8 ± 1.75 for Y90 followed by sorafenib, 2.67 ± 2.08 for Y90 followed by TACE, and 1.5 ± 0.71 for Y90 followed by bland embolization. The maximum and minimum treatment-free intervals for each group of patients are shown in Table 3 . The longest minimum treatment-free interval was observed in patients treated with isolated Y90 with a median 35.6 months (95% CI 23.8-39.4). For patients crossing over to other treatments including RFA, TACE, bland embolization, and sorafenib, median minimum treatmentfree intervals were 6.3 (95% CI 3.2-15.9), 3.4 (95% CI -4.1 to 11.4), 19.8 (95% CI -97.1 to 136.7), and 2.1 months (95% CI 0.7-6.4), respectively.
Discussion
Radioembolization is now tailored to the HCC patient's unique disease state allowing treatment from early to advanced BCLC Stages and has tolerable safety in the setting of hepatic dysfunction [4, 16] . These features are reflected in the present study as Super Survivors included BCLC Stages A through D and 12% had PVT. While we expected strong survival outcomes in patients with small solitary HCC [6] , 40% of Super Survivors had multifocal disease. Comparisons with historical controls are shown in Table 4 with Super Survivors having more favorable baseline characteristics, higher imaging response rates, and decreased toxicity overall. Values expressed as hazard ratios and 95% CI The appropriate clinical endpoint for Y90 in the treatment of HCC for improved OS is an imaging response rather than freedom from progression [17] . This is further emphasized in the present study as ALL Super Survivors had an imaging response (either WHO or EASL) in primary index lesions over the course of follow-up. The average number of Y90 treatments was 2.5 corresponding to \ 0.5 treatments per year of post-treatment survival. While multiple treatments may be required to achieve response, half of patients do not receive more than one Y90 treatment and multiple factors likely contribute: therapeutic response, toxicity, preference for alternative treatment, systemic disease progression, and survival [4] .
The overall median TTP following Y90 was 33.7 months yet the median OS for the cohort was 67.5 months. By exclusion criteria, these patients did not receive surgical intervention. Therefore, we theorize this extended survival following progression is due to the successful application of subsequent liver-directed therapies. This is further supported by the minimum treatmentfree interval of 35.6 months for isolated Y90 that mirrors the median TTP of 33.7 months. The application of segmental treatments significantly improved long-term OS in our cohort supporting the concept of radiation segmentectomy for improved preservation of liver parenchyma, especially in the absence of transplantation [11] . Dosing [ 200 Gy was not associated with improved OS or earlier response consistent with the concept of threshold dose [11, 18, 19] . Y90 dosing has not been significantly linked to imaging response, survival, or toxicity [16, 20, 21] . Interestingly, Ahmed et al. [22] have suggested use of imaging surrogates based on the targeted hepatic parenchyma within the treated angiosome which may be an area of future interest for monitoring radiation segmentectomy.
At baseline, 34/67 (50.7%) patients in our study were outside Milan criteria. Tumors were [ 5 cm on average, and 33% of patients had a previous history of cancer other than HCC. In a prospective randomized controlled trial, patients listed for transplantation who were randomized to radioembolization received liver transplantation at a rate of 87% and radioembolization offers comparable post-transplantation outcomes compared to chemoembolization [23, 24] . However, an increasing number of patients are receiving radioembolization as destination therapy, and while many centers offer curative surgery, there is an increasing role of radioembolization in the context of reduced access to surgery (i.e., resource-limited environments that cannot offer transplantation), reduced imminent need for surgery (i.e., curative hepatitis C treatments), longer transplant wait times for HCC patients (6 months before MELD 28 with some recommendations this be extended to 9 months) [25] [26] [27] .
Limitations
Our definition of Super Survivors introduces guaranteed time bias. Given the limited survival of HCC patients, such patients are rare in the absence of curative surgery so an adequate sample of untreated patients for comparison was not available. Since crossover to alternate therapies is a possible confounder, we describe these therapies in detail, including their interval timing. The TTP data were in-line with our previous experience, but it should not serve as an estimate for TTP following Y90 in all-comers since patients whose progression resulted in death prior to 3 years were excluded in our cohort by definition. Finally, our study was retrospective in nature with the usual associated limitations.
Conclusions
Long-term survival after intra-arterial therapy with radioembolization is possible in select patients. Super Survivors who lived 3 years after radioembolization spanned the BCLC staging system and had advanced age at the time of treatment yet maintained durable OS after radioembolization that was stratified by the extent of underlying liver disease at baseline. All patients achieved an imaging response. Segmental technique was associated with significantly prolonged survival suggesting a longterm benefit to this liver-sparing approach in patients who do not have surgical intervention.
